Atlas Trials

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT03580694 · TERMINATED

Trial details

NCT number
NCT03580694
Sponsor
Regeneron Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2018-06-27
Primary completion
2019-12-04
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.